PMID- 21961251
OWN - NLM
STAT- MEDLINE
DCOM- 20120419
LR  - 20111003
IS  - 1009-3591 (Print)
IS  - 1009-3591 (Linking)
VI  - 17
IP  - 9
DP  - 2011 Sep
TI  - [Update of PDE5 inhibitors for the treatment of ischemia-reperfusion].
PG  - 842-6
AB  - Phosphodiesterase type 5 (PDE5) inhibitors are used most commonly in the 
      treatment of penile erectile dysfunction (ED). Recent studies show that PDE5 
      inhibitors are ideal drugs for treating ischemia-reperfusion injury. This review 
      focuses on the results of basic and clinical researches on PDE5 inhibitors for 
      the treatment of ischemia-reperfusion injury and provides some theoretical 
      evidence for clinical options of the drugs.
FAU - Hu, Yang-Yang
AU  - Hu YY
AD  - Department of Urology, The First Hospital Affiliated to Wenzhou Medical College, 
      Wenzhou, Zhejiang 325000, China. huyangyang0577@126.com
FAU - Wu, Zhi-Gang
AU  - Wu ZG
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhonghua Nan Ke Xue
JT  - Zhonghua nan ke xue = National journal of andrology
JID - 101093592
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - 0 (Phosphodiesterase Inhibitors)
SB  - IM
MH  - Erectile Dysfunction/*drug therapy
MH  - Humans
MH  - Male
MH  - Phosphodiesterase 5 Inhibitors/*therapeutic use
MH  - Phosphodiesterase Inhibitors/*therapeutic use
MH  - Reperfusion Injury/*drug therapy
EDAT- 2011/10/04 06:00
MHDA- 2012/04/20 06:00
CRDT- 2011/10/04 06:00
PHST- 2011/10/04 06:00 [entrez]
PHST- 2011/10/04 06:00 [pubmed]
PHST- 2012/04/20 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nan Ke Xue. 2011 Sep;17(9):842-6.